Amygdala Neurosciences
PrivateLast Round
VC Round
May 14, 2024
Total Funding Raised
$15.75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Amygdala Neurosciences operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a VC Round in May 2024.
Amygdala Neurosciences is a biopharmaceutical company that discovers and develops novel pharmacotherapies to treat substance use disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amygdala Neurosciences Comparables
Compare Amygdala Neurosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sophrosyne Pharmaceuticals | 87% | |
| STALICLA | 83% | |
| Adial Pharmaceuticals, Inc. | 77% |
For institutional investors. Book with your work email.
Amygdala Neurosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | May 14, 2024 | ||||
| Grant | Aug 1, 2023 | ||||
| VC Round | Nov 18, 2019 | ||||
| Grant | Oct 21, 2019 | ||||
| Grant | Sep 19, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Amygdala Neurosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute on Alcohol Abuse and Alcoholism | Grant |
| ABMRF/The Foundation for Alcohol Research | VC Round |
| National Institutes of Health (NIH) | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 49% MoM.
- Jan 21, 2025
Monthly visitors increased 73% MoM, reaching 1.9K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 18, 2026
Amygdala Neurosciences, Inc. explores its proprietary library of selective ALDH2 inhibitors for precision oncology, particularly colorectal cancers harboring APC mutations, which occur in approximately 70% of colorectal cancer cases.
For institutional investors. Book with your work email.
Amygdala Neurosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Amygdala Neurosciences's valuation, stock price, and market status.
Is Amygdala Neurosciences a public or private company?
Amygdala Neurosciences is a private company.
What is the current stock price of Amygdala Neurosciences?
Amygdala Neurosciences is a private company, so its shares have no public market price. Caplight tracks Amygdala Neurosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Amygdala Neurosciences worth (valuation)?
Valuation information for Amygdala Neurosciences is not publicly available.
Can I buy Amygdala Neurosciences stock?
Amygdala Neurosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Amygdala Neurosciences's last funding round?
Amygdala Neurosciences's most recent funding round was VC Round on May 14, 2024.
Who are the main investors in Amygdala Neurosciences?
Key investors in Amygdala Neurosciences include ABMRF/The Foundation for Alcohol Research.
Will Amygdala Neurosciences IPO soon?
No public IPO plans have been announced for Amygdala Neurosciences.
How can I track Amygdala Neurosciences secondary market activity?
Caplight tracks bids, offers, and trades in Amygdala Neurosciences's shares on secondary markets.